• In April 2026, AdaptHealth Corp. closed a US$1.10 billion senior secured credit facility, including a US$325 million Term Loan A, a US$325 million delayed draw term loan, and a US$450 million revolving line of credit, using part of the proceeds to refinance its existing term loan and expand liquidity.
• The new facility, put in place after rating upgrades from S&P Global Ratings and Moody’s Ratings, extends debt maturities, ties pricing to leverage, and is structured to reduce the company’s overall cost of debt once its 6.125% Senior Notes due 2028 are redeemed.
• We’ll now examine how this lower-cost, longer-maturity credit facility may influence AdaptHealth’s investment narrative and financial flexibility.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

AdaptHealth Investment Narrative Recap

To own AdaptHealth, you have to believe the shift toward home-based, value-focused care and its large capitated contract can eventually translate into consistent earnings, despite recent losses and regulatory exposure. The new US$1.10 billion credit facility mainly sharpens the balance sheet by extending maturities and potentially trimming interest expense, which could modestly support the near term catalyst of executing on that big contract, but does little to reduce policy and reimbursement risk.

The credit facility also aligns with management’s February 2026 message about disciplined capital allocation and an active M&A pipeline, where they highlighted plans to fund organic growth, debt reduction, and tuck in deals. Cheaper, longer dated debt may give AdaptHealth more room to fund the infrastructure needed for its multi year national health system contract while still addressing its history of impairments and recent net losses.

Yet, even with cheaper debt and more liquidity, investors should be aware that reimbursement pressure from upcoming CMS decisions could still...

AdaptHealth's narrative projects $4.0 billion revenue and $157.7 million earnings by 2028.

Uncover how AdaptHealth's forecasts yield a $13.12 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were assuming only about 5.4% annual revenue growth to roughly US$3.8 billion and earnings of about US$166 million, so you can see how their more cautious view on margins and digital disruption might shift again once the impact of this new, lower cost credit facility becomes clearer.

Explore 2 other fair value estimates on AdaptHealth - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AdaptHealth research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free AdaptHealth research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AdaptHealth's overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 32 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.